事件描述2024 年3 月20 日,中国生物制药发布2024 年全年业绩报告:2024 年全年实现营业收入288.7亿元(同比+10.2%),实现归母净利润35.0 亿元(同比+50.1%),实现经调整Non-HKFRS 归母净利润34.6 亿元(同比+33.5%)。事件评论收入与经调利润均达成双位数增长,利润增速快于收入。2024 年全年实现营业收入288.7亿元(同比+10.2%),实现归母...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.